Leading innovation to address chronic pain with neuromedicine
TORONTO, April 20, 2022 /CNW/ – Today, LongTermGevity is pleased to announce that they have received a Dealer’s Licence from Health Canada that allows for the possession, production, packaging, sale, transport, R&D, laboratory analysis, Special Access Program (SAP) participation and clinical trials on controlled substances including psilocybin, psilocin, 3,4-methylenedioxymethamphetamine (“MDMA”), N,N-dimethyltryptamine (“DMT”), among others.
“We are thrilled about receiving our Dealer’s Licence. Our deep expertise in organic synthesis, product development and pre-clinical testing will give us an edge in the industry by enabling in-house development of novel psychedelic medicines, delivery systems, molecules, and formulations.” Says co-founder, CEO Sena Herath.
LongTermGevity has a laboratory in Toronto to support Phase I/IIa clinical trials in the U.S. and Canada using Q112 Electrogel on patients suffering from chronic lower back pain.
Our lead product, Q112 Electrogel, which is the first product to stabilise psilocin (active ingredient in psilocybin) for transdermal delivery, is a novel, non-invasive electrotherapeutic technology that targets a profound need highlighted by the World Health Organisation and is poised to disrupt a $12b neuromodulation industry.
Q112 Electrogel uses a proven neuromodulation technique in combination with a proprietary stabilised psilocin gel that can be applied on the skin to directly target an injury site in the spinal cord to help reduce inflammation and promote nervous tissue repair.
The company is currently in the process of closing a $2m seed fundraising round, of which the majority is earmarked for clinical trials, data generation, Q112 Electrogel product development and novel molecule development. Learn more at www.longtermgevity.com
About LongTermGevity
LongTermGevity Inc. (“LTG”) is a psychedelic neuromodulation therapeutics company developing novel medications for musculoskeletal disorders. LTG’s core technology includes a proprietary transdermal psilocin neuromodulation therapy to alleviate pain, promote nervous tissue repair and improve motor function performance. LTG is focused on researching and developing rehabilitative psychedelic pharmaceuticals to treat leading causes of disabilities including chronic pain, spinal cord injury and multiple sclerosis.
SOURCE LongTermGevity
For further information: Media requiring further information or interviews, please contact: Brian Glavine, Chief Operating Officer, (416) 919-8127, [email protected]
LongTermGevity receives Health Canada Dealer’s Licence & More Canada Latest News Update
LongTermGevity receives Health Canada Dealer’s Licence & More Canada Live News
All this news that I have made and shared for you people, you will like it very much and in it we keep bringing topics for you people like every time so that you keep getting news information like trending topics and you It is our goal to be able to get
all kinds of news without going through us so that we can reach you the latest and best news for free so that you can move ahead further by getting the information of that news together with you. Later on, we will continue
to give information about more today world news update types of latest news through posts on our website so that you always keep moving forward in that news and whatever kind of information will be there, it will definitely be conveyed to you people.
LongTermGevity receives Health Canada Dealer’s Licence & More Canada Trending News Today
All this news that I have brought up to you or will be the most different and best news that you people are not going to get anywhere, along with the information breaking news today of this news, you can get other types of news along with your country and city. You will be able to get information related to, as well as you will be able to get information about what is going on around you through us for free
so that you can make yourself a knowledgeable by getting complete information about your country and state and information about news. Whatever is being given through us, I have tried to bring it to you through other websites, which you may like
very much and if you like all this news, then definitely around you. Along with the people of India, keep sharing such news necessary to your loved ones, let all the news influence them and they can move forward two steps further.
Credit Goes To News Website – This Original Content Owner News Website . This Is Not My Content So If You Want To Read Original Content You Can Follow Below Links